Corium International Inc (CORI) Expected to Announce Earnings of -$0.33 Per Share
Wall Street brokerages forecast that Corium International Inc (NASDAQ:CORI) will post earnings of ($0.33) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Corium International’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.29). Corium International reported earnings of ($0.36) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The firm is expected to report its next earnings results on Thursday, November 15th.
On average, analysts expect that Corium International will report full-year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.50). For the next year, analysts anticipate that the company will post earnings of ($1.42) per share, with EPS estimates ranging from ($1.73) to ($1.10). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Corium International.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $6.72 million. Corium International had a negative return on equity of 298.48% and a negative net margin of 155.21%.
CORI opened at $8.93 on Wednesday. The company has a market cap of $313.50 million, a price-to-earnings ratio of -5.46 and a beta of 1.45. Corium International has a 52 week low of $7.17 and a 52 week high of $13.93. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89.
In related news, CEO Peter D. Staple sold 76,341 shares of Corium International stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $8.81, for a total value of $672,564.21. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert Thomas sold 35,608 shares of Corium International stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $8.86, for a total value of $315,486.88. Following the completion of the sale, the director now owns 35,608 shares in the company, valued at $315,486.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 119,965 shares of company stock worth $1,060,275. Company insiders own 30.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of CORI. Franklin Resources Inc. boosted its stake in shares of Corium International by 115.3% in the first quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after buying an additional 1,102,910 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Corium International by 42.1% in the fourth quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock valued at $16,143,000 after buying an additional 497,615 shares in the last quarter. Royce & Associates LP boosted its stake in shares of Corium International by 99.2% in the second quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 250,300 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Corium International by 127.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after buying an additional 110,000 shares in the last quarter. Finally, Tamarack Advisers LP boosted its position in Corium International by 9.4% during the first quarter. Tamarack Advisers LP now owns 1,105,000 shares of the biopharmaceutical company’s stock worth $12,674,000 after purchasing an additional 95,000 shares in the last quarter. Hedge funds and other institutional investors own 95.26% of the company’s stock.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
See Also: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.